Eli Lilly and Oxford University to fund three-year study into IBD

9 September 2013

US drug major Eli Lilly (NYSE: LLY) has entered a partnership with Oxford University, UK, to fund a three-year investigation into individualized treatment options for patients with inflammatory bowel disease (IBD) to guide the development of future innovative therapies.

Scientists and clinicians from Lilly and the university will study hundreds of individuals with IBD with respect to disease type, severity and response to current treatments and how these may be linked to the genetic make-up of each patient. The company said it is hoped that this will support the development of innovative new medicines that benefit individual patients.

The partnership brings together the academic expertise of the Oxford Translational Gastroenterology Unit (TGU), the drug development and financial support of Lilly, with additional support and expertise of the Wellcome Trust Sanger Institute near Cambridge.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK